Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of this proprietary medicinal product is substantial. |
Clinical Added Value
| minor |
ESMYA offers a minor improvement in actual benefit (IAB IV) compared to leuprorelin in terms of tolerability in the pre-operative treatment of moderate to severe symptoms in uterine fibroids in adult women of childbearing potential. |
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
6g23k9TF1StVtGy7
